Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravenous efgartigimod in adult primary immune thrombocytopenia
NL-OMON55186Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Sep 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Efgartigimod IV with Placebo IV (2 arms). Primary endpoint: Sustained platelet count response in chronic ITP. Started Sep 2020; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON55186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55186.